Virogin Biotech Canada Ltd

2 clinical trials · Sponsor

Record	Firm	Date
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma (NCT05223816)	Virogin Biotech Canada Ltd	2024-01-24
Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors (NCT05266612)	Virogin Biotech Canada Ltd	2022-11-09

Every clearance here is in the API, with alerts when new ones post.